NAT MED: Alzheimer's disease protection gene boosts melanoma metastasis

Several studies have shown that common genetic variants of the APOE gene are the main risk factors for neurodegenerative diseases and atherosclerosis diseases, but their impact on cancer outcomes is unclear to daterecently, researchers found that, unlike the effects on Alzheimer's disease, apoE4 and APOE2 variants produce beneficial and undesirable results in melanoma, respectivelyCompared to human-derived APOE2 mice, mice that expressed human-derived APOE4 alleles showed decreased progressand and metastaticity of melanomaAPOE4 mice showed enhanced anti-tumor immune activation relative to APOE2 miceT-cell depletion experiments show that the effect of APOE genotype on the progression of melanoma is mediated by changing anti-tumor immunitycompared to Carriers of APOE2, the survival rate of melanoma patients carrying the APOE4 variant was significantly higherIt is worth noting that aPOE4 mice also showed improved results under PD1 immune checkpoint blocking compared to APOE2 miceThe survival rate of anti-PD1 immunotherapy was also improved after progress in first-line treatment with APOE4 patientsfinally, by activating the liver X receptor by the drug, APOE expression can be enhanced, anti-tumor immunity can be enhanced, in APOE4 mice showed efficacy, but no efficacy in APOE2 micetherefore, these findings suggest that pre-existing genetic genes can influence the progression and survival outcomes of future malignant tumors, and support forward-looking studies of APOE genotypes as biomarkers of melanoma outcomes and therapeutic responses